Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

A Versatile Simple Capture Assay for Assessing the Structural Integrity of MHC Multimer Reagents.

Reed BK, Chopp LB, Malo CS, Renner DN, Van Keulen VS, Girtman MA, Nevala WN, Pavelko KD, Gil D, Schrum AG, Johnson AJ, Pease LR.

PLoS One. 2015 Sep 21;10(9):e0137984. doi: 10.1371/journal.pone.0137984. eCollection 2015.

2.

Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.

Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C.

Cytometry A. 2015 Jan;87(1):37-48. doi: 10.1002/cyto.a.22575. Epub 2014 Oct 8.

3.

Tracking antigen specific CD4+ T-cells with soluble MHC molecules.

Gebe JA, Kwok WW.

Methods Mol Med. 2007;136:39-50.

PMID:
17983139
4.

Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer.

Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH.

Nat Med. 2002 Jun;8(6):631-7.

PMID:
12042816
5.

Peptide-independent stabilization of MHC class I molecules breaches cellular quality control.

Hein Z, Uchtenhagen H, Abualrous ET, Saini SK, Janßen L, Van Hateren A, Wiek C, Hanenberg H, Momburg F, Achour A, Elliott T, Springer S, Boulanger D.

J Cell Sci. 2014 Jul 1;127(Pt 13):2885-97. doi: 10.1242/jcs.145334. Epub 2014 May 7.

6.

MHC multimer technology: current status and future prospects.

Bakker AH, Schumacher TN.

Curr Opin Immunol. 2005 Aug;17(4):428-33. Review.

PMID:
15967654
7.

Multimer technologies for detection and adoptive transfer of antigen-specific T cells.

Casalegno-Garduño R, Schmitt A, Yao J, Wang X, Xu X, Freund M, Schmitt M.

Cancer Immunol Immunother. 2010 Feb;59(2):195-202. doi: 10.1007/s00262-009-0778-4. Epub 2009 Oct 22. Review.

PMID:
19847424
8.

Effector and regulatory T cells derived from the same T cell clone differ in MHC class II-peptide multimer binding.

Nolte-'t Hoen EN, Amoroso MG, Veenstra J, Grosfeld-Stulemeyer MC, van Eden W, Broeren CP, Wauben MH.

Eur J Immunol. 2004 Dec;34(12):3359-69.

9.

Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.

Reguzova AY, Karpenko LI, Mechetina LV, Belyakov IM.

Expert Rev Vaccines. 2015 Jan;14(1):69-84. doi: 10.1586/14760584.2015.962520. Epub 2014 Nov 5. Review.

PMID:
25373312
10.

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.

Bouquié R, Bonnin A, Bernardeau K, Khammari A, Dréno B, Jotereau F, Labarrière N, Lang F.

Cancer Immunol Immunother. 2009 Apr;58(4):553-66. doi: 10.1007/s00262-008-0578-2. Epub 2008 Aug 27.

PMID:
18751701
11.

Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells.

Pedersen NW, Chandran PA, Qian Y, Rebhahn J, Petersen NV, Hoff MD, White S, Lee AJ, Stanton R, Halgreen C, Jakobsen K, Mosmann T, Gouttefangeas C, Chan C, Scheuermann RH, Hadrup SR.

Front Immunol. 2017 Jul 26;8:858. doi: 10.3389/fimmu.2017.00858. eCollection 2017.

12.

Production and Thermal Exchange of Conditional Peptide-MHC I Multimers.

Luimstra JJ, Franken KLMC, Garstka MA, Drijfhout JW, Neefjes J, Ovaa H.

Curr Protoc Immunol. 2019 Sep;126(1):e85. doi: 10.1002/cpim.85.

PMID:
31483102
14.

Tracking antigen-specific CD8+ T cells in the rat using MHC class I multimers.

Duplan V, Suberbielle E, Napper CE, Joly E, Saoudi A, Gonzalez-Dunia D.

J Immunol Methods. 2007 Mar 30;320(1-2):30-9. Epub 2006 Dec 22.

PMID:
17223126
16.

Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism.

Baker BM, Scott DR, Blevins SJ, Hawse WF.

Immunol Rev. 2012 Nov;250(1):10-31. doi: 10.1111/j.1600-065X.2012.01165.x. Review.

PMID:
23046120
17.

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V.

J Mol Recognit. 1993 Jun;6(2):81-94.

PMID:
7508238
18.
19.

The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8+ T-cells by multimer technology in Adoptive Immunotherapy.

Beloki L, Ciáurriz M, Mansilla C, Bandrés E, Rodríguez-Calvillo M, Ramírez N, Olavarría E.

J Immunol Methods. 2013 Oct 31;396(1-2):168-72. doi: 10.1016/j.jim.2013.07.014. Epub 2013 Aug 6.

PMID:
23933324

Supplemental Content

Support Center